Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330469 | 0.98 | FABP4 (0.39) | FABP4FABP5ALDH1A1CA2FAAH | |
| SCHEMBL30252249 | 0.94 | FABP4 (0.36) | FABP4FABP5ALDH1A1CA2SMN1; SMN2 | |
| SCHEMBL2722431 | 0.90 | CA2 (0.39) | FABP4FABP5ALDH1A1CA2SMN1; SMN2 | |
| SCHEMBL16409213 | 0.82 | CTSL (0.34) | ALDH1A1CA2SMN1; SMN2CTSL | |
| SCHEMBL23794142 | 0.80 | ALDH1A1 (0.36) | FABP4FABP5ALDH1A1FAAHCYP1A2 | |
| SCHEMBL19388569 | 0.78 | CTSS (0.33) | CA2CTSL | |
| SCHEMBL16391617 | 0.78 | EPHX1 (0.36) | ALDH1A1CA2SMN1; SMN2CTSL | |
| SCHEMBL10808711 | 0.76 | ALDH1A1 (0.40) | FABP4FABP5ALDH1A1USP2HTT | |
| SCHEMBL9947946 | 0.76 | CA2 (0.34) | ALDH1A1CA2SMN1; SMN2 | |
| SCHEMBL16391416 | 0.76 | FABP4 (0.36) | FABP4FABP5ALDH1A1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-0552712-B1 | 8-(1-Aminocycloalkyl)-1,3-dialkylxanthine derivatives as antagonists adenosine receptors | FOSCAMA BIOMED CHIM FARMA (IT) | 1998-11-25 | — | — | EP | disclosed |
| US-5378844-A | ADENOSINE ANTAGONIST | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1995-01-03 | — | — | US | disclosed |
| CN-1082047-A | 8-(the amino cycloalkyl of 1-) 1,3-dialkyl xanthine derivative | FOSCAMA BIOMED CHIM FARMA (IT) | 1994-02-16 | — | — | CN | disclosed |
| EP-0552712-A1 | 8-(1-Aminocycloalkyl)-1,3-dialkylxanthine derivatives as antagonists adenosine receptors | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | FABP4 3471/4885FABP5 1171/4885ALDH1A1 3966/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | FABP4 3471/4885FABP5 1171/4885ALDH1A1 3966/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | FABP4 3419/4885FABP5 1586/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.